Analyze AAV capsids & transgenes with one method
With our newest assay, gene therapy bioprocessing and manufacturing scientists run in-process testing for capsids and transgenes at the required depth of analysis, in a single workflow and on a single platform.
Optimizing amount of controls versus quality of controls
In traditional gene therapy workflows, scientists typically choose between
Capsid ELISA + dPCR
Lower quality, higher frequency
Requires manufacturers to develop complex assays, run two separate workflows and reconcile data from two analytical methods (compounding errors1).
AUC / CD-MS
Lower frequency, higher quality
Requires highly specialized training and expensive equipment that is hard to roll out in a (c)GMP environment. Typically only possible at a couple of samples per day.
Characterize capsid and gene quality in one workflow
We have unified the most essential steps in an AAV-based gene therapy QC into a workflow that’s as simple as running an ELISA. Our workflow works from crude samples and can be executed in under 3 hours and requires a minimal amount of training. Our generated data is a single quantified value and easy to interpret.
Rewatch our AAV product launch
Analyze directly from crude samples
No purification steps, no DNA isolation, no complex sample prep. Our platform works from sample volumes as little as 2µL and works directly on crude samples.
Full/empty/partial characterization
With 3 different assay variants, you can accurately determine viral capsid titer, transgene titer (and transgene at the desired level of granularity).
One workflow, one training
Single workflow combining capsid and transgene titration assays. The platform features a familiar ELISA-like setup that deploys seamlessly in manual and automated workflows
How it works
Add sample to nanoplate
Add detection antibody
Add Nano amplifier and read
Testing for capsids and genes have always been part of either one complex workflow or two separate ones. With NanoMosaic’s process, we’re seeing great results in bringing these two together, at high throughput, with the full/ empty/ partial resolution of lower throughput methods.
Tal Raz
Vice-President of Biology at NanoMosaic
Production grade platform
Tessie and our Nanoplates are designed to work in cGMP environments, with 21 CFR Part 11 support in our software and excellent CVs and reproducibility across technicians.
Wide dynamic range
Excellent dynamic range between 1.0E+08 to 1.0E+10.
Low cross-user CV
Highly repeatable with CV’s <10% across multiple runs, assays, technicians and instruments.
Start simplifying your AAV production quality control
Learn more about NanoMosaic’s platform.
Join our AAV launch event
We’re formally launching our AAV capsid & transgene titer assay on the 26th of March, 2024. We’ll be joined by early users from University of Massachussets to discuss their experience.
Register for our AAV product launch26th of March
45
Days
12
Hours
44
Mins
29
Secs